NYSE:AIM
AIM ImmunoTech Inc.
AIM ImmunoTech Inc.'s revenue fell 48.2% in fiscal 2025 to $88,000 while operating margin fell to −13254.5%. The diluted share count rose 189.0%.Summary generated from AIM ImmunoTech Inc.'s SEC filings. Latest annual report filed Mar 27, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$88,000
Revenue growth−48.2%
Revenue, 5-yr CAGR−11.6%
Gross marginn/a
Operating margin−13254.5%
Net margin−15861.4%
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+189.0%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating income | −19 | −20 | −32 | −20 | −12 |
| Net income | −19 | −19 | −29 | −17 | −14 |
| Free cash flow | −14 | −16 | n/a | −15 | n/a |
Recent filings
- DEF 14AProxy statement
Sep 30, 2026 - 4Insider transaction report
Sep 18, 2026 - 4Insider transaction report
Sep 17, 2026 - 8-KEntry into a material agreement
Sep 14, 2026 - 8-KEntry into a material agreement
Sep 10, 2026 - 8-KEntry into a material agreement
Sep 4, 2026 - 8-KRegulation FD disclosure
Aug 11, 2026 - 8-KResults of operations and financial condition
Aug 10, 2026